Pharmaceutical companies responsible for some of the biggest price hikes in recent years earned bipartisan condemnation at a recent hearing of a Senate committee. 

Turing Pharmaceuticals, Valeant Pharmaceuticals, Retrophin Inc. and Rodelis Therapeutics were criticized by members of the Senate Special Committee on Aging for buying the rights to life-saving drugs and then dramatically hiking their price. Increasingly, companies backed by hedge-funds and other venture capital have been scooping up some of the top off-patent medications. 

"The Turing and Valeant price spikes have been egregious," Sen. Susan Collins, R-Maine, the committee chair, said at a hearing Wednesday. Her Democratic counterpart on the committee, Missouri Sen. Claire McCaskill, voiced similar suspicion in an interview with NPR. 

Continue Reading for Free

Register and gain access to:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Consumer Driven Health Care
Broker Regulation